Enzo Biochem (NYSE:ENZ) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ) in a report issued on Thursday. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Price Performance

ENZ opened at $0.74 on Thursday. The stock has a fifty day moving average price of $0.97 and a 200 day moving average price of $1.07. Enzo Biochem has a 1 year low of $0.68 and a 1 year high of $1.44.

Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings results on Monday, December 16th. The medical research company reported ($0.05) EPS for the quarter. Enzo Biochem had a negative return on equity of 11.84% and a negative net margin of 81.73%.

Enzo Biochem Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, December 2nd. Stockholders of record on Friday, November 15th were paid a dividend of $0.10 per share. The ex-dividend date was Friday, November 15th. This represents a $0.40 annualized dividend and a dividend yield of 54.35%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. BBR Partners LLC bought a new stake in Enzo Biochem during the third quarter worth approximately $112,000. Renaissance Technologies LLC lifted its stake in shares of Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after buying an additional 64,417 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Enzo Biochem by 94.5% during the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after buying an additional 13,735 shares during the period. Finally, Geode Capital Management LLC grew its stake in Enzo Biochem by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after buying an additional 11,742 shares during the last quarter. 36.90% of the stock is owned by institutional investors.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.